黑色素瘤相关抗原/黑色素-A抗体

黑色素瘤相关抗原/黑色素-A抗体

英文名称    Melan A    

中文名称    黑色素瘤相关抗原/黑色素-A抗体    

别    名    Protein Melan-A; Antigen LB39 AA; Melanoma HMB45; Antigen SK29 AA; Antigen SK29-AA; CMM 1; CMM; CMM1; Cutaneous Malignant Melanoma Dysplastic Nevus; DNS; Dysplastic Nevus Syndrome; FAMMM; MART1; melan A; Melan A protein; Melanoma antigen recognized by T-cells 1; MLM; Monophenol monooxygenase; Tumor rejection antigen AB; tyrosinase; Melanoma HMB45; Melanoma; Melan-A; MART-1; MAR1_HUMAN.      

研究领域    肿瘤  细胞生物  免疫学  t-淋巴细胞      

抗体来源    Rabbit    

克隆类型    Polyclonal    

交叉反应    Human, Mouse, Rat,     

产品应用    WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.    

分 子 量    13kDa    

细胞定位    细胞浆     

性    状    Lyophilized or Liquid    

浓    度    1mg/ml    

免 疫 原    KLH conjugated synthetic peptide derived from mouse Melan A:1-80/113     

亚    型    IgG    

纯化方法    affinity purified by Protein A    

储 存 液    0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.    

保存条件    Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.    

PubMed    PubMed    

产品介绍    Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients.